

EXPRESS MAIL NO.: <u>EV 452 773 871 US</u>

Sheet 1 of 9

TRADE	10177-211-999 (Cam No. 008563-999208)	09/910,388	
LIST OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)	APPLICANT Kunz et al.		
	FILING DATE	GROUP 1050	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
4K/	A01	4,391,797	07/05/83	Folkman et al.			
	A02	4,768,507	09/06/88	Fischell et al.			
	A03	5,019,096	05/28/91	Fox et al.			
	A04	5,474,563	12/12/95	Myler et al.			
	A05	5,512,055	04/30/96	Domb et al.			
	A06	5,567,417	10/22/96	Sasisekharan et al.			·
	A07	5,616,608	04/01/97	Kinsella et al.			· · · · · ·
	A08	6,403,635 B1	06/11/02	Kinsella et al.			
			1				

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
-1.0		I == 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -					YES	NO
111	B01	EP 0 260 066	03/16/88	European				
1 1	B02	EP 0 297 946	01/04/89	European				
	B03	EP 0 365 863	05/02/90	European				
	B04	EP 0 374 044	06/20/90	European				
the	B05	EP 0 411 893	02/06/91	European				
	B06	EP 0 451 202	10/16/91	European				
	B07	EP 0 470 569 A1	08/06/91	European				
	B08	EP 0 526 102	02/03/93	European				
	B09	EP 0 543 653 A1	05/26/93	European				
	B10-	EP 0 567 816 A1	04/08/93	European				
	BII	EP 0 568 310 A1	04/27/93	European				
	B12	EP 0 577 215	01/05/93	European				
	B13	EP 0 588 518	03/23/94	European			 	
1	B14	EP 0 606 613	07/20/94	European				
6	B15	EP 0 622 076	11/02/94	European				
1	B16	EP 0 623 354 A1	11/09/94	European				
	B17	EP 0 623 354 B1	10/02/02	European				
HR	B18	EP 0 691 130	01/10/96	European				
	B19	-EP-0-7-1-1-158-B-1-	-1-2/03/03-	European				
1-	B20	EP 1 181 943 A1	02/27/02	European				
1	B21	WO 85/00107	01/17/85	PCT				
\ <i>Y</i> .	B21	WO 88/10259	12/29/88	PCT				

EXPRESS MAIL NO.: EV 452 773 871 US

heet 2 of 9

								
HIR	- 1	B23	WO 90/01969	03/08/90	PCT			
HR	<u></u>	B24	WO 90/11676	10/18/90	PCT			
	1	B25	WO 90/12597	11/01/90	PCT			
	Ti	B26	WO 90/13293	11/15/90	PCT			
V	ı	B27	WO 90/13332	11/15/90	PCT			
+1/2	7	B28	WO 91/07154	05/30/91	PCT			
	ı	B29	WO 91/10424	07/25/91	PCT			
	ī	B30	WO 91/11193	08/08/91	PCT			
7	1	B31	WO 91/12779	09/05/91	PCT			
	1	B32	WO 91/12846	09/05/91	PCT			
	ī	B33	WO 91/15219	10/14/91	PCT			
V	ī	B34	WO 91/15222	10/17/91	PCT			
THE	J	B35	WO 91/17731	11/28/91	PCT			
	1	B36	WO 92/08480	05/29/92	PCT			
	1	B37	WO 92/10210	06/25/92	PCT			
	1	B38	WO 92/11872	07/23/92	PCT			
	1	B39	WO 92/11890	07/23/92	PCT			
	Ī	B 40	WO 92/11895	07/23/92	PCT			
	1	B41	WO 92/12717	08/06/92	PCT			
	1	B42	·WO 92/15286	02/21/02	PCT			
	1	B43	WO 92/18546	10/29/92	PCT			
1	1	B44	WO 92/19273	11/12/92	PCT			
	1	B45	WO 92/21363	12/10/92	PCT			
V	1	B46	WO 93/06792	04/15/93	PCT			
HIR	7	B47	WO 93/07748	04/29/93	PCT			
i	T ₁	B48	WO 93/09790	05/27/93	PCT		-	
		B49	WO 93/11120	06/10/93	PCT			
. 1	ī	B50	WO 93/16687	09/02/93	PCT			
	1	B51	WO 93/17121	09/02/93	PCT			
. [ī	B52	WO 93/17669	09/16/93	PCT			
	1	B53	WO 93/24476	12/09/93	PCT			
	1	B54	WO 94/03644	02/17/94	PCT			
	1	B55	WO 94/04164	03/03/94	PCT .			
	1	B56	WO 94/04178	03/03/94	PCT			
	1	B57	WO 94/07529	04/14/94	PCT			
	1	B58	WO 94/08604	04/28/94	PCT			
	,	B59	WO 94/08605	04/28/94	PCT			
		B60	WO 94/15590	07/21/94	PCT			
		B61	WO 94/15646	07/21/94	PCT			
		B62	WO 94/16706	08/04/94	PCT			
		B63	WO 94/17786	08/18/94	PCT			
		B64	WO 94/18345	08/18/94	-PCT-	 -		
		B65	WO 94/18954	09/01/94	PCT			1
	1	B66	WO 94/18967	09/01/94	PCT			
	7	B67	WO 94/18968	09/01/04	PCT			
					<u> </u>	 		<u> </u>

AR	B68	WO 94/19000	09/01/94	PCT
	B69	WO 94/19001	09/01/94	PCT .
	B70	WO 94/19003	09/01/94	PCT
	B71	WO 94/20096	09/25/94	PCT
	B72	WO 94/20097	09/15/94	PCT
Ť	B73	WO 94/21308	09/29/94	PCT
	B74	WO 94/21679	09/29/94	PCT
	B75	WO 94/22436	10/13/94	PCT
	B76	WO 94/25020	11/10/94	PCT
1	B77	WO 94/28721	12/22/94	PCT
	B78	WO 95/03036	02/02/95	PCT
V	B79	WO 95/03795	02/02/95	PCT

	<u> </u>	
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
118	COI	"Cytochalasins", In: The Merck Index, Eleventh Edition, Merck & Co., Rahway NJ, 438-439 (1989).
1	C02	"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev L/07/92
	C03	Allemann, et al., "Drug Loaded Poly(Lactic Acid) Nanoparticles Produced by a Reversible Salting-out Process: Purification of an Injectable Dosage Form," Eur. J. Pharm. Biopharm., Vol. 39 (1), pp. 13-18 (1993)
SAS	C04	Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor β ₁ Interleukin, and β ₂ -Microglobulin Plasma Levels," Kidney International, Vol. 40, pp. 1110-1117 (1991)
	C05	Aschermann, M., "Restenosis After Percutaneous Transluminal Coronary Angioplasty Pathophysiology, New Trends in Prevention and Treatment," Cor. Vasa., 36:211-218 (1994)
the	C06	Assoian, et al., "Type β Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells," The Journal of Cell Biology, Vol. 102, pp. 1217-1223 (1986)
T	C07	Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions" Int'l J. Pharm, 52 165-171 (1989)
	C08	Bagdade, et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition," J. of Clinical Endocrinology and Metabolism, Vol. 70, No. 4, pp. 1132-35 (1990)
	C09	Bamburg, James R., "Biological and Biochemical Actions of Trichothecene Mycotoxins," Progress in Molecular and Subcellular Biology", (Hahn F.E., et al., ed.), Springer-Verlag, pp. 41-110) (1983)
- FIR	C10	Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury," JACC, Vol. 13, No. 2, p. 252A Abstract (1989)
HAC	CII	Barbacid, et al., "Binding of [acetyl-14 C] Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes," Eur. J. Biochem. 44, pp. 437-444 (1974)
	C12	Bartoli et al. "In vitro and in vivo antitumoral activity of free, and encapsulated taxol". J. Microencapsulation, 7 (2):191-197, 1990
	C13	Beck, et al., "Poly(DL-Lactide-co-glycolide) /Norethisterone Microcapsules: An Injectable Biodegradable Contraceptive," Biology of Reproduction, Vol. 28, pp. 186-195 (1983)
	C14	Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels," Breast Cancer Res. and Treatment, Vol. 12, pp. 307-310 (1988)
	C15	Bogyo, et al., "Cytochalasin-β-Induced Immunosuppression of Murine Allogeneic Anti-tumor Response and the Effect of Recombinant Human Interleukin-2," Cancer Immunol. Immunother, Vol. 32, pp. 400-405 (1991)
	C16	Bousquet, et al., "Effects of Cytochalasin β in Culture and in Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma," Cancer Res., Vol. 50, pp. 1431-39 (1990)
	C17	Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs," J. Urol. Vol. 130, No. 6, pp. 1208-10 (1983)
	C18	Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988)
	C19	Burnol, et al., "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," PNAS (USA), Vol. 79, pp. 1245-49 (1982)
	C20	Butta, et al., "Induction of Transforming Growth Factor β ₁ in Human Breast Cancer in vivo Following
<u> </u>	 	Tamoxifen Treatment," Cancer Res. Vol. 52, pp. 4261-64 (1992) Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restensis: Targeting of Fibroblast
	C21	Growth Factor Receptors", Proc. Natl. Acad. Sci. USA, 89, 7159-7163 (1992)
	C22	Chaldakov, et al., "Cyclic AMP-and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization," Cell Tissue Res. Vol. 255, pp. 435-442 (1989)
-		

412	C23	Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-lodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer," Cancer Research, Vol. 51, pp. 5851-5858 (1991)
7110	↓ ——	
	C24	Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome," Cytokine, Vol. 3, No. 4, pp. 292-298 (1991)
7	C25	Chapman, et al., "A Bioabsorbable Stent: Initial Experimental Results," Supplement III Cir., Vol. 82, No. 4, p.
		III-72 (1990)
	C26	Clowes et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery," Cir. Res. Vol. 56, No. 1, pp. 139-145 (1985)
	C27	Clowes, et al. "Mechanisms of Stenosis After Arterial Injury", Laboratory Investigation, Vol. 49, No. 2, pp. 208-215 (1983)
	C28	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - I. Smooth Muscle Growth in the Absence of Endothelium", Laboratory Investigation, Vol. 49, No. 3, pp. 327-333 (1983)
	C29	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - III, Endothelial and Smooth Muscle Growth in Chronically Denuded Vessels", Laboratory Investigation, Vol. 54, No. 3, pp. 295-303 (1986)
1	C30	Cohen, et al., "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres,"
- }-	C31	Pharmaceutical Research, Vol. 8, No. 6, pp. 713-720 (1991) Cole, R. J. et al., "The Cytochalasins", In: Handbook of Toxic Fungal Metabolics, Academic Press, New York,
	1	p. 264-265, 281-282 (1981) Coomber and Gotlieb "In vitro endothelial wound repair. Interaction of cell migration and proliferation".
HR	C32	Ateriosclerosis, 10 (2):215-222, 1990
1/	C33	Cowsar, et al., "Poly(Lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," Methods in Enzymology, Vol. 112, pp. 101-117 (1985)
	C34	Cox et al., "Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries". Coronary Artery Disease, 3:237-248, 1992
	C35	Cox et al., "Local Delivery of Heperin and methotrexate fails to inhibit in vivo smooth muscle cell
	+	proliferation". Circulation Suppl. 84(4):II-71, #0284, 1991 Crissman, et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression
	C36	Through the G ₁ Phase of the Cell Cycle," <i>PNAS (USA)</i> , Vol. 88, pp. 7580-84 (1991)
1	C37	Danielpour, David, "Improved Sandwich Enzyme-Linked Immunosorbent Assays for Transforming Growth Factor," Journal of Immunological Methods, Vol. 158, pp. 17-25 (1993)
	C38	Danielpour, et al., "Evidence for Differential Regulator of TGF\$1 and TGF\$2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays," Annals New York Academy of Sciences, pp. 300-302
-	C39	Danielpour, et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta
1	C39	(TGF-1 and TGF-2) Secreted by Cells in Culture," Journal of Cellular Physiology, Vol. 138, pp. 79-86 (1989)
\ \	C40	Dasch, et al., "Capture Immunoassays Specific for TGF1 and TGF2: Use in Pharmacokinetic Studies," Annals New York Academy of Sciences, pp. 303-305
	C41	Detre, et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", The New England J. of Med., Vol 318, No. 5, pp. 265-270 (1988)
	C42	Dimond, Patricia F., Ph.D., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes," Genetic Engineering News, pp. 7 & 19 (1993)
	C43	Ebner, et al., "Cloning of a Type 1 TGF-β Receptor and Its Effect on TGF-β Binding to the Type II Receptor," Science, Vol. 260, pp. 1344-48 (1993)
	C44	Eldridge, et al., "Biodegradable and Biocompatible Poly(DL-Lactide-CO-Glycolide) Microspheres as an
	C44	Adjuvant for Staphylococcal Enterotoxin B Toxoid which Enhances the Level of Toxin-Neutralizing Antibodies," Infection and Immunity, 59(9):2978-2986 (1991)
	C45	Epstein, Stephen E., MD., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating
		Vascular Smooth Muscle Cells," Cir. Vol. 84, No. 2, pp. 778-787 (1991)
	C46	Ettenson and Gotlieb "Centrosomes, Microtubules, and Microfilaments in the Reendothelialization and Remodeling of Double-Sided In Vitro Wounds". Laboratory Investigation, Vol. 68, No. 6, pp. 722-733, 1992, United States and Canadian Academy of Pathology, Inc.
	C47	Fanelli, et al., "Restenosis Following Coronary Angioplasty", Amer. Heart J., Vol 119, No. 2, Part 1, pp. 357-368 (1990)
	C48	Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium," Br. J. Pharmacol. Vol. 107, pp. 679-683 (1992)
	C49	Faxon et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", Arteriosclerosis, Vol. 4, No. 3, pp. 189-195 (1984)
	C50-	Fay, et al., "Effects of Gytochalasin-B-On-The-Uptake of Ascorbic Acid-and-Glucose By-3T3. Fibroblasts:
	C50	Mechanism of Impaired Ascorbate Transport in Diabetes," Life Sci., Vol. 46, pp. 619-624 (1990) (USA)
ľ	C51	Feelisch, et al., "Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and
1	<i>l</i>	Endothelial Cells," Biochemical and Biophysical Research Communications, Vol. 180, No. 1, pp. 286-293 (1991)
	<u>'</u>	11.55.

		<u> </u>
the	P C52	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", Exp. Mol. Pathol., 43 288-296 (1985)
	C53	Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies: JACC, 17, 758-769, (1991)
$\overline{}$	C54	Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", Prog. Colloid and Polymer Sci.,
	034	56, 16-20 (1975)
	C55	Fulop, et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes Under Various Stimuli," Immunobiol., Vol. 171, pp. 302-310 (1986)
	C56	Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface," J. Cell Biol. Vol. 103, pp 1699-1710 (1986)
	C57	Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", International Journal of Pharmaceutics, 69, 193-196 (1991)
	C58	Gasco, M. R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection:, Intl. J. of Pharmaceut, 62 119-123 (1990)
	C59	Glagov, et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries," New England J. of
	C60	Med., Vol. 316 No. 22, p. 1371-1375 (1987) Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to
		Horseradish Peroxidase," Atherosclerosis, Vol. 65, pp. 215-225 (1987) Grainger, et al., "Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing
	C61	transforming growth factor-like activity from serum," Cardiovascular Research, Vol 27, pp. 2238-47 (1993)
	C62	Grainger, et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells in Culture by Inducing Production of Transforming Growth Factor β," Biochem J. Vol. 294, pp. 109-112 (1993)
	C63	Grainger, et al., A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular Smooth-Muscle Cells," <i>Biochem. J.</i> Vol. 277, pp. 145-151 (1991)
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	C64	Grainger, et al., Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth Muscle Cells," Biochem. J. Vol. 283, p. 403-408 (1992)
-1	C65	Gregory, et al. "Effects of Treatment with Cyclosporine, FK 506, Rapamycin, Mycophenolic Acid, or
		Deoxyspergualin on Vascular Muscle Proliferation in Vivo," Transplantation Proceedings, 25:770-771 (1993)
	C66	Hanke, et al., Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin," Circulation, Vol 85, No. 4, pp. 1548-56 (1992)
	C67	Harpel, et al., "Plasmin Catalyzes Binding of Lipoprotein (α) to Immobilized Fibrinogen and Fibrin," Proc. Natl Acad. Sci. USA, Vol. 86, pp. 3847-3851 (1989)
	C68	Heldin, et al., "Demonstration of an Antibody Against Platelet-derived Growth Factor," Experimental Cell Research," Vol. 136, pp. 255-261 (1981)
	C69	Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols," J. of Polymer Science: Polymer Letters Edition, Vol. 18, pp. 298-297 (1980)
	C70	Henriksson, et al., "Hormonal Regulation of Serum Lp (α) Levels; J. Clin. Invest. Vol. 89, p. 1166-1171 (1992)
	. C71	Hermans et al., "Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet"" American Heart Journal, 122 (1) Part, 1, 171-187, 1991
.	C72	Hirata et al., "Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate". Arthritis and Reumatism, 32(9): 1065-1073, 1989
	C73	Hoff, et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by
-+	C74	Macrophages," Arteriosclerosis, Vol. 9, No. 4, pp. 538-549 (1989) Hoffman, et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and
	072	Nitrogen Mustard by Inhibitors of Protein Kinase C," Int. J. Cancer, Vol. 42, pp. 382-388 (1988) Holland, et al., "Atherogenic Levels of Low-density Lipoprotein Increase Endocytotic Activity in Cultured
	C75	Human Endothelial Cells," Amer. J. of Pathology, Vol. 140, No. 3, pp. 551-558 (1992)
	C76	Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1 and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture." Exp. Cell Res., 200, 358-360 (1992)
	C77	Jampel et al., "In vitro release of hydrophobic drugs from polyanhydride disks". Ophthal Surg, 23 (11):676-680, 1991
Ť	C78	Jarvis, et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica," Chemistry of Alleopathy, pp. 149-159 (1985)
	C79	Jarvis, et al., "Macrocylic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance," Acc. Chem. Res. 15 pp. 338-395 (1982)
	-C80-	Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues,"
1		Supp. II Circulation, Vol. 78, No. 4, p. II-82 (1988)
		Jordan, V. Craig, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept
	C81	to Clinical Trials," Hormones, Cell Biol. and Cancer: Perspectives and Potentials, pp. 105-123 (1988)

THE		50 775-787 (1988)
13.	C83	Kambic, et al., "Biomaterials in Artificial Organs," Chemical & Engineering News, pp. 31-48 (1986)
	C84	Kemp et al., "The Id Gene is Activated by Serum But is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells," Biochem. J. (Great Britain), Vol. 277, pp. 285-288 (1991)
	C85	Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells" Cell, 48 417-428
	C86	Koff, et al., "Negative Regulation of GI in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGI β, Science, Vol. 260, pp. 536-538 (1993)
	C87	Kovach, et al., "Serial Intravascular Ultrasound Studies Indicate That Chronic Recoil Is An Important Mechanism Of Restenosis Following Transcatheter Therapy," JACC Vol. 484A, Abstract 835-3 (1993)
	C88	LaFont, et al., "Post-angioplasty Restenosis In The Atherosclerotic Rabbit: Proliferative Response Or Chronic Constriction?," Circulation, Vol. 88, I-521, Abstract 2806 (1993)
	C89	Lambert et al., "A new method for arterial drug delivery via removable stent". JACC, 21(2):483A, #834-2, 199
1	C90	Lambert, et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs,"
-\	C91	Coronary Artery Disease, Vol. 4, No. 5, pp. 469-475 (1993) Lefer, Allen M., "Role of Transforming Growth Factor β in Cardioprotection of the Ischemic-Reperfused Myocardium," Growth Factors and the Cardiovascular System, Chapter 14 (Cummins, P. ed.), Kluwer
		Academic Publishers, pp. 249-260 (1993)
	C92	Lefer, et al., "Mechanism of the Cardioprotective Effect of Transforming Growth Factor β ₁ , in Feline Myocardial Ischemia and Reperfusion," PNAS (USA), Vol. 90, pp. 1018-22 (1993)
	C93	Lefer, et al., "Mediation of Cardioprotection by Transforming Growth Factor-β," Science, Vol. 249, pp. 61-64 (1990)
	C94	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", Intl. J. Pharmaceut. ,66, 29-37 (1990)
	C95	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemical Abstracts, 121, 580: Abstract No. 263625g (1994)
	C96	Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", Biochimica et Biophysica Acta, 1042, 42-50 (1990)
	C97	Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and Is Chemotactic for Smooth Muscle Cells In Vitro," Cir. Res. Vol. 74, No. 2, pp. 214-224 (1994)
	C98	Lin, et al., "Expression Cloning of the TGF-β Type II Receptor, a Functional Transmembrane Serine/Threoning Kinase," Cell. Vol. 68, pp. 775-785 (1992)
	C99	Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", Drug Development and Industrial Pharmacy, 16, 899-920
ĺ	C100	
	C101	Liu, et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia," Circulation, Vol. 79, No. 6, pp. 1374-87 (1989)
.	C102	Love, et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women," Annals of Internal Medicine, Vol. 115, No. 11, pp. 860-864 (1991)
	C103	Love, et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer," J. of the National Cancer Institute, Vol. 82, No. 16, pp. 1327-32 (1990)
	C104	Maione, Theodore E. and Sharpe, Richard J. "Development of angiogenesis inhibitors for clinical applications' TiPS- Nov. 1990 [Vol. 11]
	C105	Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", J. Pharm. Pharmacol, 42 6p, (1990)
	C106	
	C107	Mang, Tien-Dung Duc, "Distribution to Normal and Tumor Tissues of Cytochalasin B After Intravenous Administration in Mice," Thesis Submitted for Honors B.S. in Biology, Syracuse University
	C108	
	C109	McCaffrey, et al., "Transforming Growth Factor; β Activity is Potentiated by Heparin Via Dissociation of the Transforming Growth FactMacroglobulin Inactive Complex," The J. of Cell Biology, Vol. 109, pp. 441-448 (1989)
	C110	McCarroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-f (TGF-β) by Endothelial Cells in Culture, Clin.—Chem.—Vol36; No6, pp1-152-(-1990)-Abstract-No0934-
	CIII	McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention," Carcinogenesis, Vol. 7, No. 2, pp. 193-196 (1986)
\ /	C112	

		McLean, et al., "cDNA Sequence of Human Apolipoprotein(a) is Homologous to Plasminogen," Nature, Vol.
He	C113	330, No. 6143, pp. 132-137 (1987)
	C114	
		Science in Biology in the Graduate School of Syracuse University, published Syracuse University, Biology Dept. (1988)
	C115	Merrilees, et al., "Synthesis of TGF-β ₁ by Vascular Endothelial Cells is Correlated with Cell Spreading," J. Vasc. Res., Vol. 29, pp. 376-384 (1992)
	C116	
	C117	
	C118	
	C119	
	C120	Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", Science, 244, 1342-1344 (1983)
	C121	Naito, et al., "Vascular Endothelial Cell Migration In Vitro Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System," Artery, Vol. 17(1), pp. 21-31 (1989)
	C122	Nakao, et al., "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid," Atherosclerosis, Vol. 46, pp. 309-319 (1983)
	C123	
	C124	
	C125	OID!
	C126	
	C127	
	C128	
	C129	Oliveira, et al., "Isolation and Characterization of Smooth Muscle Cell Membranes," Biochimica et Biophysica Acta. Vol. 332, pp. 221-232 (1974)
	C130	
	C131	Osipow, "Transparent Emulsion" J. Soc. Cosmetic Chemists, 277-285 (1963).
	C132	Palmaz et al., "Intravascular Stents", Advances in Vascular Surgery, 1, 107-135 (1993).
	C133	Pardee, et al., "Control of Cell Proliferation," Cancer, Vol. 39, pp. 2747-54 (June Supplement 1977)
	C134	Pathak, et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", International Journal of Pharmaceutics, 65, 1690175 (1990)
	C135	Podzimek, et al., "O/W Microemulsions", J. Dispersion Science and Technology, I, 341-359 (1980)
	C136	Popma, et al., "Factors Influencing Restenosis After Coronary Angioplasty", The Amer. J. of Med. Vol. 88, pp. 1-16N - 1-24N (1990)
	C137	Post, et al., "Restenosis Is Partly Due To Intimal Hyperplasia And Partly To Remodeling Of The Injured Arteri Wall," European Heart J., Vol. 14, p. 201, Abstract P1164 (1993)
	C138	Post, et al., "Which Part Of The Angiographic Diameter Reduction After Balloon Dilation Is Due To Intimal Hyperplasia?", JACC, Vol. 21, 36A, Abstract, 851-95 (1993)
	C139	Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", International Journal of Pharmaceutics, 27, 335-348, (1985)
	C140	Powell et al., "Suppression of the Vascular Response to Injury: The Role of Angiotensin-Converting Enzyme Inhibitors", JACC, 17, 137B-142B-(1991).——————————————————————————————————
	C141	The state of the s
	C142	7 11 1 17
V	C143	Ross, et al., "Chronic Inflammation, PDGF, TGF, and Smooth Muscle Proliferation, Abstracts from the 20th

		Annual Meeting of the Keystone Symposia on Molecular Biology, Session on Molecular Mechanisms of
· LHA		Vascular Disease, J. Cell Biochem. S15C, Abstract No. G006, p. 96 (1991)
	C144	Ross, Russell, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s, Nature, Vol. 362, pp. 801-09 (1993)
	C145	C. I. I. M. C. I. C. I. D. C. I. C. I. C. I. Discovering Colored and Trade at a large
	C146	Sanders, et al., "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres," Journal of Pharmaceutical Sciences, Vol. 73, No. 9, pp. 1294-1297 (1984)
	C147	
	C148	Schlingemann, et al., Expression of the High Molecular Weight Melanoma-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds," Amer. J. Pathology, Vol. 136, No. 6, pp. 1393-1405 (1990)
	C149	
	C150	CT 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	C151	C. L. C. D. U. A. C. D. U. A. C. L. D. L. C.
	C152	Schwartz, et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms," JACC, Vol. 20, No. 5, pp. 1284-93 (1992)
	C153	Shananhan, et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells," Circulation Research, Vol. 73, No. 1 (1993)
	C154	1345 (1992)
	C155	Lipid Microspheres," J. Pharm. Pharmacol. 38:118-121 (1985)
ì	C156	No. 0326, p. II-82, (1988)
25.7	C157	of Cell Biology, Vol. 95, pp. 667-671 (1982)
المعتب	C158	Smooth Muscle Cells," American J. of Pathology, Vol. 137, No. 2 (1990)
	C159	265, 391-394 (1994)
	C160	Model", Circulation Research, 57 105-112 (1985)
!!	C161	Streuli, et al., "Extracellular Matrix Regulators Expression of the TGF-\(\beta\)1 Gene," The J. of Cell Biol. Vol. 120 No. 1, pp. 253-260 (1993)
	C162	Suckling, Keith E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature," <i>Biochem. Society Transactions</i> , Vol. 21, pp. 660-662 (1993)
	C163	Tamm, Ch. Basel, "The Antibiotic Complex of the Verrucarins and Roridins," Fortschr. Chem. Org. Naturst., 31:65 117 (1974)
ij	C164	Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and Rheumatism, 36 (9) Suppl.:S45, 1993
il l	C165	Tice, et al., "Biodegradable controlled-release parental systems" Pharmaceutical Technology, 26-35 (1984)
	C166	Topol, Eric J., "The Restenosis "Antitheory", Mayo Clinic Proc. Vol. 68, pp. 88-90 (1993)
	C167	Vanhoutte, P.M., "Hypercholesterolemia, Atherosclerosis And Release Of Endothelium-Derived Relaxing Factor By Aggregating Platelets," European Heart J. Vol. 12, Supplement E. pp. 25-32 (1991)
	C168	Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery," Br. J. Pharmacol., Vol. 109, pp. 612-617 (1993)
##: 	C169	Vijayagopal, et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor," Biochem. J., Vol. 289, pp. 837-844 (1993) (GB)
	C170	Vijayagopal, et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholesteryl Ester Accumulation Foam Cells from Rabbit Atherosclerotic Lesions," J. Clin. Invest. Vol. 91, pp. 1011-18 (1993)
	C171	Voisard, et al., "The In-Vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries," Coronary Artery Disease, 4:935-942 (1993)
.Ilw	C172	

EXPRESS MAIL NO.: EV 452 773 871 US Sheet 9 of 9

1 /10	10	C173	Wakefield, et al., "Latent Transforming Growth Factor β from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences," The Journal of Biological Chemistry, Vol. 263, No. 16, pp. 7646-
1 ##	K-		7654 (1988)
		C174	than Active Transforming Growth Factor, I, and a Different Tissue Distribution," The Journal of Clinical Investigation, Inc., Vol. 86, pp. 1976-1984 (1990)
		C175	proliferation," Cardiovascular Res., Vol. 27, pp. 1191-98 (1993)
		C176	Weissberg, et al., "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Comitogenic with Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells," Atherosclerosis, Vol. 85, pp. 257-262 (1990)
		C177	Cardiovascular System, (Cummins, P.ed), Kluwer Academic Publishers, p. 189-205 (1993)
		C178	by Elizabeth D. Hay, PLENUM PRESS, NEW YORK CHAPTER 2, pp. 45-78 (1991)
		C179	Wight, et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation," Current Opinion in Cell Biol. Vol. 4, pp. 793-801 (1992)
		C180	Wight, Thomas N., "Cell Biology of Arterial Proteoglycans," Arteriosclerosis, Vol. 9, No. 1., pp. 1-20 (1989)
		C181	Wilensky, et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty," American Heart Journal, Vol. 122, No. 4, pp. 1136-1140 (1991)
		C182	Wolinsky, et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery, JACC, Vol. 15, No. 2, pp. 475-81 (1990)
		C183	THE STATE OF THE S
V		C184	

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
(AMINER	DATE CONSIDERED 1/23/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.